Eucreas 50 mg/1000 mg Tablets (Generic Equivalent)

Cheap Generic for Eucreas 50 mg/1000 mg (ildagliptin 50 mg, metformin hydrochloride 1000 mg) is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

The health and medical information provided here is for general purposes only and is not a substitute for the expertise and judgment of your physician, or other health care professional. It should not be understood to indicate that the use of this medicine is safe, appropriate or effective for you. Always consult your health care professional before using this, or any other, drug.

Do not take Generic for Eucreas 50 mg/1000 mg (ildagliptin 50 mg, metformin hydrochloride 1000 mg) as a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes.
Lactic acidosis is a very rare but serious metabolic complication that can occur due to metformin accumulation.
Rare cases of hepatic dysfunction (including hepatitis) have been reported with vildagliptin. LFTs should be performed prior to the initiation of treatment with Eucreas in order to know the patient`s baseline value. Liver function should be monitored during treatment with Eucreas at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Eucreas.
Following withdrawal of treatment with Eucreas and LFT normalisation, treatment with Eucreas should not be re-initiated.
Metformin is contraindicated in patients with heart failure, therefore Eucreas is contraindicated in this patient population.
Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.
Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain.
As Eucreas contains metformin, the treatment should be discontinued 48 hours before elective surgery with general anaesthesia and should not usually be resumed earlier than 48 hours afterwards.

There have been no therapeutic clinical trials conducted with Eucreas.
The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose.
Rare cases of hepatic dysfunction (including hepatitis) have been reported with vildagliptin. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment.
Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an ACE inhibitor. The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.

Take Generic for Eucreas 50 mg/1000 mg (ildagliptin 50 mg, metformin hydrochloride 1000 mg) exactly as prescribed by your doctor.Based on the patient`s current dose of metformin, Eucreas may be initiated at either the 50 mg/850 mg or 50 mg/1000 mg tablet strength twice daily, one tablet in the morning and the other in the evening. The recommended daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
Patients receiving vildagliptin and metformin from separate tablets may be switched to Eucreas containing the same doses of each component.
Doses higher than 100 mg of vildagliptin are not recommended.
There is no clinical experience of vildagliptin and metformin in triple combination with other antidiabetic agents.
Taking Eucreas with or just after food may reduce gastrointestinal symptoms associated with metformin.